Gene Therapy Market to Reach $36.55 Billion by 2032, Driven by Rising Demand for Curative Treatments and Expanding Clinical Pipeline
According to MarketsandMarkets™,The global gene therapy market is projected to grow from USD 8.85 billion in 2024 to USD 36.55 billion by 2032, at an impressive CAGR of 19.4% during the forecast period. This rapid growth is driven by increasing demand for curative therapies targeting genetic disorders, rare diseases, and certain types of cancer, along with a robust and expanding clinical trial pipeline.
Browse 660 market data Tables and 60 Figures spread through 433 Pages and in-depth TOC on “Gene Therapy Market”.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=122857962
According to market insights, approximately 19 gene therapy products are expected to be launched between 2026 and 2032, collectively contributing nearly 25% of the projected market value by 2032. Advancements in gene editing technologies, vector engineering, and delivery systems are further accelerating innovation and commercialization in this space.
However, high treatment costs and limited manufacturing scalability remain key challenges, potentially restricting broader adoption and access to gene therapies.
Neurology Segment Leads by Therapeutic Area
By therapeutic area, the neurology segment accounted for the largest share of the gene therapy market in 2023 and is expected to maintain its dominance throughout the forecast period. This growth is primarily driven by the increasing number of gene therapy products targeting neurological and neuromuscular disorders.
Significant focus on conditions such as spinal muscular atrophy (SMA), Duchenne muscular dystrophy (DMD), and limb-girdle muscular dystrophy (LGMD) is contributing to the expansion of this segment. The high unmet need for effective treatments for rare neurological disorders continues to drive research and development efforts in this area.
In Vivo Delivery Method Dominates the Market
Based on delivery method, the in vivo segment held the largest share of the gene therapy market in 2023 and is also expected to register the fastest growth. This dominance is attributed to the widespread use of in vivo approaches in commercially available gene therapies.
In vivo delivery offers several advantages, including direct administration into the patient’s body, reduced complexity compared to ex vivo methods, and broader applicability across multiple therapeutic areas. Additionally, a significant portion of the clinical pipeline is focused on in vivo strategies, further reinforcing its leading position.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=122857962
North America Maintains Market Leadership
Regionally, North America accounted for the largest share of the gene therapy market. This leadership is driven by the strong presence of leading biotechnology and pharmaceutical companies, increasing regulatory approvals by the US Food and Drug Administration (FDA), and substantial investments in research and development.
The region also benefits from a well-established healthcare infrastructure, favorable regulatory frameworks, and growing adoption of advanced therapies, all of which contribute to sustained market growth.
Competitive Landscape
Key players operating in the gene therapy market include Biogen Inc., Novartis AG, Alnylam Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., Jazz Pharmaceuticals Plc, Ferring B.V., Pfizer Inc., Amgen, Inc., Johnson & Johnson Services, Inc., Daiichi Sankyo Company, Limited, BioMarin Pharmaceutical Inc., Kyowa Kirin Co., Ltd., Nippon Shinyaku Co., Ltd., PTC Therapeutics, UniQure NV, CRISPR Therapeutics, bluebird bio, Inc., Krystal Biotech, Inc., and Ultragenyx Pharmaceutical Inc., among others.
These companies are actively investing in pipeline expansion, strategic collaborations, and advanced manufacturing capabilities to strengthen their market position and accelerate the development of next-generation gene therapies.
Related Reports:
In Vitro Diagnostics Market – Global Forecast to 2030
Bioinformatics Market – Global Forecast to 2031
Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/gene-therapy-market-122857962.html
